2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …

Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …

Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …

Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …

Background Current guidelines recommend potent platelet inhibition with ticagrelor or
prasugrel in patients after an acute coronary syndrome. However, data about optimal …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …